Balchem Corporation (BCPC)
NEUTRALFundamental
71
Precio
$177.89
Capitalización Bursátil
$5.79B
Parte 1 · Cuánto vale la empresa
Resumen
Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment offers specialty vitamin K2; microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; methylsulfonylmethane; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment distributes ethylene oxide and ammonia primarily for use in the health care industry; and single use canisters for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. It sells its products through sales force, independent distributors, and sales agents. The company was incorporated in 1967 and is headquartered in Montvale, New Jersey.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance y Liquidez
Ingresos
$1.09B
Últimos 12 meses (hasta 30/6/2026)
Beneficio Neto
$164M
Últimos 12 meses (hasta 30/6/2026)
Flujo de Caja Libre
-
Patrimonio Neto Total
$1.26B
Pasivo Total
$429M
Ratio de Liquidez
2.66
Cobertura de Intereses
-
Deuda/EBITDA
0.65
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$126.59
Precio Actual
$177.89
Margen de Seguridad
-40.5%
Rango de Valor Justo
$82.29 - $170.90
Métodos de Estimación
Métricas de Valoración
Ratio P/E
34.87
ROE
12.3%
Ratio P/B
4.34
P/FCF
-
Margen Bruto
36.3%
ROIC
10.9%
Radar de Rentabilidad
Value Creation (Economic Moat)
ROIC
10.9%
WACC
9.0%
ROIC − WACC
+2.0 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Criterios de Análisis Fundamental
Superado (17)
- EPS shows upward trend
- EPS CAGR 10.73%
- Price CAGR 8.01%
- ROIC 11.0%
- Gross Margin 36.3%
- Debt/Equity ratio
- Operating Margin 20.2%
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- ROE 12.8%
- Revenue Growth 5Y 8.1%
- Analyst Consensus 78% Buy
- Earnings Quality (OCF/NI) 1.34
- Share Dilution -0.3%
- Net Margin Trend 15.1% vs 14.5%
- Piotroski F-Score 9/9
Fallido (6)
- P/B Ratio 4.34
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Earnings Surprise avg 0.9%
- PEG Ratio 2.72
No disponible (5)
- P/FCF NaN
- Dividend Payout NaN%
- Positive Free Cash Flow
- CapEx intensity
- Interest Coverage
Piotroski F-Score
Solidez financiera fuerte
Calidad de los Beneficios
Alta calidad: beneficios respaldados por efectivo
Dilución de Acciones
Recomprando acciones. Favorable para el accionista
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Mr. Theodore Lee Harris | CEO, President & Chairman | 60 |
| Mr. Carl Martin Bengtsson | Executive VP, CFO, Treasurer and GM of Animal Nutrition & Health | 48 |
| Ms. Hatsuki Miyata J.D. | Executive VP, Chief Legal Officer & Secretary | 49 |
| Mr. M. Brent Tignor | Senior VP & Chief Human Resources Officer | 47 |
| Mr. Frederic Boned | Senior VP, Head of Digital Transformation & AI and GM of Human Nutrition & Health | 46 |
| Ms. Erin L. Gilson | VP & Chief Accounting Officer | - |
| Mr. Martin Luther Reid | Senior VP & Chief Supply Chain Officer | 58 |
| Mr. Job L. van Gunsteren | Senior VP & GM of Specialty Products | 48 |
| Mr. George Graham | Senior VP and Chief R&D Officer | 55 |
Riesgo de Auditoría
3
Riesgo del Consejo
4
Riesgo de Compensación
4
Riesgo de Derechos del Accionista
7
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Latest News
Recent headlines for BCPC, sourced from Markets Gazette.